Evidence map›Paper›PMID 24790830›Full record

ArticleSpringerPlus2014

SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics.

Inmaculada Palanca-Maresca, Belén Ruiz-Antorán, Gustavo Centeno-Soto, Sara Jiménez-Fernandez, Lourdes García-Murillo, Ana Siles, Sandra Villagrá, Hilario Blasco-Fontecilla, Luis Iruela-Cuadrado, Enriqueta Roman-Riechman and 2 more

Open access · diamondAbstract read
In one paragraph

Article in SpringerPlus, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Inmaculada Palanca-MarescaDepartment of Psychiatry, Puerta de Hierro University Hospital, Madrid, Spain ; Calle Manuel de Falla, 1, 28222 Majadahonda, Madrid, Spain.
Belén Ruiz-AntoránDepartment of Clinical Pharmacology, Puerta de Hierro University Hospital, Madrid, Spain.
Gustavo Centeno-SotoDepartment of Clinical Pharmacology, Puerta de Hierro University Hospital, Madrid, Spain.
Sara Jiménez-FernandezDepartment of Psychiatry, Granada University, Granada, Spain.
Lourdes García-MurilloNYU Child Study Center, New York University, New York, USA.
Ana SilesDepartment of Cardiology, Puerta de Hierro University Hospital, Madrid, Spain.
Sandra VillagráDepartment of Pediatric Cardiology, La Paz University Hospital, Madrid, Spain.
Hilario Blasco-FontecillaDepartment of Psychiatry, Puerta de Hierro University Hospital, CIBERSAM, Madrid, Spain.
Luis Iruela-CuadradoDepartment of Psychiatry, Puerta de Hierro University Hospital, Madrid, Spain.
Enriqueta Roman-RiechmanDepartment of Pediatrics, Puerta de Hierro University Hospital, Madrid, Spain.
Cristina Avendaño-SoláDepartment of Clinical Pharmacology, Puerta de Hierro University Hospital, Madrid, Spain.
Christoph U CorrellThe Zucker Hillside Hospital, Psychiatry Research, Glen Oaks, New York, USA.
Hospital Universitario Puerta de Hierro Majadahonda · ESCentro de Investigación Biomédica en Red de Salud Mental · ESHospital Universitario La Paz · ESNew York University · USUniversidad de Granada · ESZucker Hillside Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite drastic increases in antipsychotic prescribing in youth, data are still limited regarding their safety in this vulnerable population, necessitating additional tools for capturing long-term, real world data.

methodsWe present SENTIA (SafEty of NeurolepTics in Infancy and Adolescence; https://SENTIA.es), an online registry created in 2010 to track antipsychotic adverse effects in Spanish youth <18 years old currently taking or initiating with any antipsychotic treatment. SENTIA collects information on sociodemographic, diagnostic and treatment characteristics, past personal medical/psychiatric history, healthy lifestyle habits and treatment adherence. Additionally, efficacy and adverse effect data are recorded including the Children's Global Assessment Scale; Clinical Global Impressions scale for Severity and Improvement, the Safety Monitoring Uniform Report Form, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, vital signs, blood pressure, and EKG. Finally, fasting blood is drawn for hematology, electrolytes, renal, liver and thyroid function, glucose, insulin, lipid, prolactin and sex hormone levels. Initially, a diagnostic interview and several psychopathology scales were also included. Patients are assessed regularly and followed even beyond stopping antipsychotics.

resultsSince 01/17/2011, 85 youth (11.5 ± 2.9 (range = 4-17) years old, 70.6% male) have been included at one inaugural center. After a mean duration of 17 ± 11 (range = 1-34) months, 78.8% are still actively followed. For feasibility reasons, the diagnostic interview and detailed psychopathology scales were dropped. The remaining data can be entered in <30 minutes. Several additional centers are currently being added to SENTIA.

conclusionsImplementation of a systematic online pharmacovigilance system for antipsychotic adverse effects in youth is feasible and promises to generate important information.

Indexed as

AdolescentsAdverse effectsAntipsychoticsChildrenPharmacovigilanceRegistry

Identifiers

PMID24790830
PMCPMC4000597
OpenAlexW2142038823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.